

Gene panel information

| | |
|------------------------|------------------------------------|
| Gene panel | ALS |
| Version | 5 |
| Total genes | 43 |
| Activation date | Friday 21 march 2025 |
| Publisher | Center for Medical Genetics, Ghent |

Genes

| Gene | % at least 20 x covered* | OMIM gene id | OMIM Phenotypes |
|----------------|--------------------------|--------------|---|
| ALS2 | 99.87 % | 606352 | Primary lateral sclerosis, juvenile, 606353 (3), Autosomal recessive; Spastic paralysis, infantile onset ascending, 607225 (3), Autosomal recessive; Amyotrophic lateral sclerosis 2, juvenile, 205100 (3), Autosomal recessive |
| ANG | 100 % | 105850 | Amyotrophic lateral sclerosis 9, 611895 (3) |
| ANXA11 | 99.71 % | 602572 | Amyotrophic lateral sclerosis 23, 617839 (3), Autosomal dominant; Inclusion body myopathy and brain white matter abnormalities, 619733 (3), Autosomal dominant |
| CCNF | 99.99 % | 600227 | Frontotemporal dementia and/or amyotrophic lateral sclerosis 5, 619141 (3), Autosomal dominant |
| CHCHD10 | 100 % | 615903 | ?Myopathy, isolated mitochondrial, autosomal dominant, 616209 (3), Autosomal dominant; Spinal muscular atrophy, Jokela type, 615048 (3), Autosomal dominant; Frontotemporal dementia and/or amyotrophic lateral sclerosis 2, 615911 (3), Autosomal dominant |
| CHMP2B | 99.8 % | 609512 | Frontotemporal dementia and/or amyotrophic lateral sclerosis 7, 600795 (3), Autosomal dominant |
| CYLD | 99.46 % | 605018 | Brooke-Spiegler syndrome, 605041 (3), Autosomal dominant; Cylindromatosis, familial, 132700 (3), Autosomal dominant; Trichoepithelioma, multiple familial, 1, 601606 (3), Autosomal dominant; ?Frontotemporal dementia and/or amyotrophic lateral sclerosis 8, 619132 (3), Autosomal dominant |
| DCTN1 | 99.98 % | 601143 | Perry syndrome, 168605 (3), Autosomal dominant; {Amyotrophic lateral sclerosis, susceptibility to}, 105400 (3), Autosomal dominant, Autosomal recessive; Neuropathy, distal hereditary motor, autosomal dominant 14, 607641 (3), Autosomal dominant |
| DNAJC7 | 99.88 % | 601964 | No OMIM phenotypes |
| ERBB4 | 99.92 % | 600543 | Amyotrophic lateral sclerosis 19, 615515 (3), Autosomal dominant |
| FIG4 | 99.83 % | 609390 | Yunis-Varon syndrome, 216340 (3), Autosomal recessive; ?Polymicrogyria, bilateral temporooccipital, 612691 (3), Autosomal recessive; Amyotrophic lateral sclerosis 11, 612577 (3), Autosomal dominant; Charcot-Marie-Tooth disease, type 4J, 611228 (3), Autosomal recessive |
| FUS | 99.93 % | 137070 | Amyotrophic lateral sclerosis 6, with or without frontotemporal dementia, 608030 (3); Essential tremor, hereditary, 4, 614782 (3), Autosomal dominant |
| GRN | 100 % | 138945 | Frontotemporal dementia 2, 607485 (3), Autosomal dominant, Autosomal recessive; Aphasia, primary progressive, 607485 (3), Autosomal dominant, Autosomal recessive; Ceroid lipofuscinosis, neuronal, 11, 614706 (3), Autosomal recessive |
| HNRNPA1 | 62.92 % | 164017 | ?Inclusion body myopathy with early-onset Paget disease without frontotemporal dementia 3, 615424 (3), Autosomal dominant; ?Myopathy, distal, 3, 610099 (3), Autosomal dominant; Amyotrophic lateral sclerosis 20, 615426 (3), Autosomal dominant |

| Gene | % at least 20 x covered* | OMIM gene id | OMIM Phenotypes |
|------------------|--------------------------------|-----------------|--|
| HNRNPA2B1 | 99.9 % | 600124 | Oculopharyngeal muscular dystrophy 2, 620460 (3), Autosomal dominant; ?Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 2, 615422 (3), Autosomal dominant |
| KIF5A | 99.91 % | 602821 | Myoclonus, intractable, neonatal, 617235 (3), Autosomal dominant; {Amyotrophic lateral sclerosis, susceptibility to, 25}, 617921 (3), Autosomal dominant; Spastic paraplegia 10, autosomal dominant, 604187 (3), Autosomal dominant |
| LRP12 | 99.99 % | 618299 | Oculopharyngodistal myopathy 1, 164310 (3), Autosomal dominant; Amyotrophic lateral sclerosis 28, 620452 (3), Autosomal dominant |
| MATR3 | 99.86 % | 164015 | Amyotrophic lateral sclerosis 21, 606070 (3), Autosomal dominant |
| NEFH | 100 % | 162230 | Charcot-Marie-Tooth disease, axonal, type 2CC, 616924 (3), Autosomal dominant; {?Amyotrophic lateral sclerosis, susceptibility to}, 105400 (3), Autosomal dominant, Autosomal recessive |
| NEK1 | 99.83 % | 604588 | Short-rib thoracic dysplasia 6 with or without polydactyly, 263520 (3), Digenic recessive, Autosomal recessive; ?Orofaciodigital syndrome II, 252100 (3), Autosomal recessive; {Amyotrophic lateral sclerosis, susceptibility to, 24}, 617892 (3), Autosomal dominant |
| OPTN | 99.98 % | 602432 | Glaucoma 1, open angle, E, 137760 (3), Autosomal dominant; Amyotrophic lateral sclerosis 12 with or without frontotemporal dementia, 613435 (3), Autosomal dominant, Autosomal recessive; {Glaucoma, normal tension, susceptibility to}, 606657 (3) |
| PFN1 | 74.59 % | 176610 | Amyotrophic lateral sclerosis 18, 614808 (3) |
| PRPH | 99.98 % | 170710 | {Amyotrophic lateral sclerosis, susceptibility to}, 105400 (3), Autosomal dominant, Autosomal recessive |
| SETX | 99.97 % | 608465 | Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2, 606002 (3), Autosomal recessive; Amyotrophic lateral sclerosis 4, juvenile, 602433 (3), Autosomal dominant |
| SIGMAR1 | 99.99 % | 601978 | ?Neuronopathy, distal hereditary motor, autosomal recessive 2, 605726 (3), Autosomal recessive; ?Amyotrophic lateral sclerosis 16, juvenile, 614373 (3), Autosomal recessive |
| SLC52A1 | 100 % | 607883 | Riboflavin deficiency, 615026 (3), Autosomal dominant |
| SLC52A2 | 100 % | 607882 | Brown-Vialetto-Van Laere syndrome 2, 614707 (3), Autosomal recessive |
| SLC52A3 | 99.94 % | 613350 | ?Fazio-Londe disease, 211500 (3), Autosomal recessive; Brown-Vialetto-Van Laere syndrome 1, 211530 (3), Autosomal recessive |
| SOD1 | 99.97 % | 147450 | Spastic tetraplegia and axial hypotonia, progressive, 618598 (3), Autosomal recessive; Amyotrophic lateral sclerosis 1, 105400 (3), Autosomal dominant, Autosomal recessive |
| SPAST | 99.77 % | 604277 | Spastic paraplegia 4, autosomal dominant, 182601 (3), Autosomal dominant |
| SPG11 | 99.89 % | 610844 | Amyotrophic lateral sclerosis 5, juvenile, 602099 (3), Autosomal recessive; Charcot-Marie-Tooth disease, axonal, type 2X, 616668 (3), Autosomal recessive; Spastic paraplegia 11, autosomal recessive, 604360 (3), Autosomal recessive |
| SPTLC1 | 99.74 % | 605712 | Amyotrophic lateral sclerosis 27, juvenile, 620285 (3), Autosomal dominant; Neuropathy, hereditary sensory and autonomic, type IA, 162400 (3), Autosomal dominant |
| SPTLC2 | 99.95 % | 605713 | Neuropathy, hereditary sensory and autonomic, type IC, 613640 (3), Autosomal dominant |
| SQSTM1 | 100 % | 601530 | Neurodegeneration with ataxia, dystonia, and gaze palsy, childhood-onset, 617145 (3), Autosomal recessive; Frontotemporal dementia and/or amyotrophic lateral sclerosis 3, 616437 (3), Autosomal dominant; Myopathy, distal, with rimmed vacuoles, 617158 (3), Autosomal dominant; Paget disease of bone 3, 167250 (3), Autosomal dominant |

ALS

Gene panel

| Gene | % at least 20 x covered* | OMIM gene id | OMIM Phenotypes |
|---------------|--------------------------------|-----------------|---|
| TAF15 | 99.91 % | 601574 | Chondrosarcoma, extraskeletal myxoid, 612237 (1) |
| TARDBP | 100 % | 605078 | Frontotemporal lobar degeneration, TARDBP-related, 612069 (3), Autosomal dominant; Amyotrophic lateral sclerosis 10, with or without FTD, 612069 (3), Autosomal dominant |
| TBK1 | 99.07 % | 604834 | {Encephalopathy, acute, infection-induced (herpes-specific), susceptibility to, 8}, 617900 (3), Autosomal dominant; Frontotemporal dementia and/or amyotrophic lateral sclerosis 4, 616439 (3), Autosomal dominant; Autoinflammation with arthritis and vasculitis, 620880 (3), Autosomal recessive |
| TIA1 | 99.72 % | 603518 | Welander distal myopathy, 604454 (3), Autosomal dominant, Autosomal recessive; Amyotrophic lateral sclerosis 26 with or without frontotemporal dementia, 619133 (3), Autosomal dominant |
| TUBA4A | 100 % | 191110 | Amyotrophic lateral sclerosis 22 with or without frontotemporal dementia, 616208 (3), Autosomal dominant |
| UBQLN2 | 100 % | 300264 | Amyotrophic lateral sclerosis 15, with or without frontotemporal dementia, 300857 (3), X-linked dominant |
| UNC13A | 99.99 % | 609894 | No OMIM phenotypes |
| VAPB | 100 % | 605704 | Spinal muscular atrophy, late-onset, Finkel type, 182980 (3), Autosomal dominant; Amyotrophic lateral sclerosis 8, 608627 (3), Autosomal dominant |
| VCP | 99.99 % | 601023 | Frontotemporal dementia and/or amyotrophic lateral sclerosis 6, 613954 (3), Autosomal dominant; Charcot-Marie-Tooth disease, type 2Y, 616687 (3), Autosomal dominant; Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia 1, 167320 (3), Autosomal dominant |

Explanation

OMIM release used for OMIM disease identifiers and descriptions: **2024-09-05**

Gene symbols used are according to the HGNC guidelines (corresponding to Ensembl database release 105).

Each Phenotype is followed by its MIM number, phenotype mapping key and inheritance pattern.

Possible phenotype mapping keys

- (1) the disorder is placed on the map based on its association with a gene, but the underlying defect is not known
- (2) the disorder has been placed on the map by linkage; no mutation has been found
- (3) the molecular basis for the disorder is known; a mutation has been found in the gene
- (4) a contiguous gene deletion or duplication syndrome, multiple genes are deleted or duplicated causing the phenotype

Brackets, "[]", indicate "nondiseases," mainly genetic variations that lead to apparently abnormal laboratory test values (e.g., dysalbuminemic euthyroidal hyperthyroxinemia).

Braces, "{ }", indicate mutations that contribute to susceptibility to multifactorial disorders (e.g., diabetes, asthma) or to susceptibility to infection (e.g., malaria).

A question mark, "?", before the phenotype name indicates that the relationship between the phenotype and gene is provisional. More details about this relationship are provided in the comment field of the map and in the gene and phenotype OMIM entries.

* The column '% at least 20 x covered' shows the percentage of the coding sequence (+/-20 nucleotides of the flanking introns) of that gene that is on average at least 20 x covered. This according to the experience with exome sequencing in our laboratory and based on the current method.